Post on 04-Jan-2016
European Federation of Statisticians in the
Pharmaceutical Industry(EFSPI)
July 2015
What is EFSPI?
• EFSPI = European Federation of Statisticians in the Pharmaceutical
Industry
• Founded in 1992
• EFSPI is an “umbrella”, non-profit making organisation
• A federation of National European Groups
• Now have 10 national groups
• No individual members
• Our national organisations collectively represent 2800 members
• Each organisation has 2 members on the EFSPI Council
• Website: www.efspi.org
2
BelgiumBelgiumSBS/BVSSBS/BVS
DenmarkDenmarkDSBSDSBS
Finland Finland SSLSSL
FranceFranceSFdSSFdS
GermanyGermanyAPFAPF
ItalyItalyBIASBIAS
NetherlandsNetherlandsPSDMPSDM
SwedenSwedenFMSFMS
SwitzerlandSwitzerlandBBSBBS
United KingdomUnited KingdomPSIPSI
EFSPI members
3
BelgiumBelgiumSBS/BVSSBS/BVS
DenmarkDenmarkDSBSDSBS
Finland SSLFinland SSL
FranceFranceSFdSSFdS
GermanyGermanyAPFAPF
ItalyItalyBIASBIAS
NetherlandsNetherlandsPSDMPSDM
SwedenSwedenFMSFMS
SwitzerlandSwitzerlandBBSBBS
United KingdomUnited KingdomPSIPSI
EFSPI Council Members
Emmanuel Quinaux, An Vandenbosch
Arne Haahr Andreasen, Birgitte Biilmann Rønn
Teppo Huttunen, Sami Virtanen
François Aubin, Maylis Coste
Christoph Gerlinger, Frank Langer
Giampaolo GiacovelliPaolo Morelli
Egbert Biesheuvel, Stefan Driessen
Mattis Gottlow , Magnus Kjaer
Marisa Bacchi, Hans Ulrich Burger
Mark Morris,Chrissie Fletcher
4
EFSPI Objectives
• To promote professional standards of statistics and the standing of
the statistical profession in the pharmaceutical industry
• To offer a collective expert input on statistical matters to national and
international authorities and organisations
• To exchange information on and harmonise attitudes to the practise
of statistics in the European Pharma Industry and within member
groups
5
EFSPI Officers and Key Roles ( 2015)
• President / Communications – Chrissie Fletcher
• Vice-President – Marisa Bacchi
• Treasurer – Birgitte Biilmann Rønn
• Scientific Lead – Egbert Biesheuvel
• Regulatory Lead – Christoph Gerlinger
• Statistical Leaders Chair – Stefan Driessen
• Website – Francois Aubin
• EFSPI Executive Office – Julie Mellish, KSAM 6
EFSPI Activities
• Regulatory Affairs (joint committee with PSI)
• co-ordinates review of regulatory guidance within EU Statistical
Community
• Works with Scientific to identify topics for scientific debate
• Scientific
• Organise series of scientific forums for discussion and
collaboration
• Share and disseminate materials to EU Statistical Community
• Communications
• Distribute quarterly newsletters, and seek collaborations with
other relevant associations
• Statistical Leaders Meeting
7
EFSPI – Regulatory affairs
• For example input in FDA guideline on non-inferiority
8
EFSPI – Regulatory affairs
• For example viewpoint on data transparency
9
EFSPI – Scientific Affairs
2015 (current plan):
• EFSPI/BBS Health Technology Assessment meeting
• PSI/EFSPI Estimands and sensitivity analyses meeting
• EFSPI Late Phase Dose finding studies meeting
• EFSPI Biomarkers and subgroup analyses meeting
2014:
• EFSPI Health Technology Assessment meeting
• BBS/EFSPI Data transparency meeting
2013:
• EFSPI/BBS Health Technology Assessment meeting
• EFSPI/PSI Structured benefit-risk assessment meeting
• EFSPI Survival analysis and its applications meeting
• EFSPI Data transparency workshop
10
EFSPI – Communications
www.efspi.org
11
Monthly newsletters
New website
Statistics Leaders Meetings
• Forum of senior statistics leaders in EU from across the industry
(managers and key opinion leaders in statistics)
• Meets annually (since 2010) to discuss and address strategic
challenges, enabling networking and exchange of information on
key developments in the industry
• Opportunities for SIGs to bring topics for scientific discussion
and seek advice/direction
• Share key news and use email distribution list to seek input
between meetings, may hold adhoc teleconferences as needed
12
EU Statistical Leaders – key topics discussed in previous meetings
13
IntegratedData Analysis
Leadership and managing through change
Data transparency Emerging trends in statistics
Current SIGs*
• Biomarker (leader = Athula Herath, heratha@MedImmune.com )
• Benefit-risk (leader = Alexander Schacht, schacht_alexander@lilly.com )
• Health Technology Assessment, HTA (leader = Chrissie Fletcher, fletcher@amgen.com )
• Integrated Data Analysis (leader = Byron Jones, byron.jones@novartis.com)
• Medical Devices (leader = Roland Marion-Gallois , roland.marion-gallois@medtronic.com )
• Modelling & Simulation (leader = Chris Campbell, ccampbell@mango-solutions.com )
• Real World data (leader = George Quartey, quarteyg@gene.com )
• Toxicology (leader = Gareth Thomas, ThomasG@UKOrg.Huntingdon.com)
* Majority of SIGs formed under leadership of PSI and subsequently expanded to include EFSPI members
14
EFSPI working group on data sharing
• Lead Sally Hollis (AZ) and Uli Burger (Roche) • Objectives:
– To identify and prospectively prioritize statistical issues in data transparency
– To co-ordinate statistical contributions across Europe to the data transparency debate
– To disseminate relevant information on the topic across the statistical community
– To develop and share a vision of the potential longer term impact of data transparency.
1515
EFSPI working group on data sharing
• Five work streams– Providing continuous input in EMA/EFPIA
(Christoph Gerlinger, Bayer, Chrissie Fletcher, Amgen)
– Recommendations for re-analysis practices (Chrissie Fletcher, Amgen, Sally Hollis, AstraZeneca)– Future impact on biostatistics
(Nick Manamley , Amgen)– Minimal requirements for data sharing
(Rebecca Sudlow , Roche, Janice Branson, Novartis)– Ensuring patient data confidentiality
(Katherine Tucker, Roche)
1616
European Federation of Statisticians in the
Pharmaceutical Industry(EFSPI)
For more information, visit our website:
www.efspi.org